PDF(Pubmed)
Abstract：
Neurotrophic keratitis or keratopathy (NK) is a degenerative corneal disease induced by impairment of the trigeminal nerve function. This condition may lead to persistent epithelial defects, corneal ulceration, and perforation. The diagnosis of NK requires a careful investigation of any ocular and systemic condition associated with the disease and ocular surface and corneal sensitivity examinations. In the past, several medical and surgical procedures were used to treat this condition with different clinical effectiveness. Cenegermin is a recombinant human nerve growth factor (rh-NGF) that supports corneal reinnervation. Different clinical trials have demonstrated the safety and efficacy of topical cenegermin in patients with moderate to severe neurotrophic keratitis. In this review, we report the literature on clinical results regarding the treatment of NK with cenegermin since its approval by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in 2017 and 2018, respectively.
摘要：
神经营养性角膜炎或角膜病变（NK）是由三叉神经功能受损引起的退行性角膜疾病。这种情况可能导致持续的上皮缺陷，角膜溃疡,和穿孔。NK的诊断需要仔细研究与疾病相关的任何眼部和全身状况以及眼表和角膜敏感性检查。在过去,使用了几种内科和外科方法来治疗这种疾病，但临床效果不同。Cenegermin是支持角膜神经支配的重组人神经生长因子(rh-NGF)。不同的临床试验已经证明了局部cenegermin在中度至重度神经营养性角膜炎患者中的安全性和有效性。在这次审查中,我们分别报道了自2017年和2018年欧洲药品管理局(EMA)和食品和药品管理局(FDA)批准使用cenegermin治疗NK的临床结果文献.
